CHRNA4 and opioid use disorder: While there is interest in using nAChR antagonists to treat tobacco use in a manner similar to that underlying the use of the μ‐opioid antagonist naltrexone as a treatment for opioid use disorder, these results suggest that antagonists may be limited in their capacity to function as smoking cessation aids.